About this episode
In this episode, Bernie Marini and Anthony Perissinotti chat with special guest Charles Foucar, MD, a hematology specialist and expert in the field. We discuss the controversial FDA approval of ivosidenib in combination with azacitidine in newly diagnosed IDH1+ AML, based on the results of the AGILE study: https://www.nejm.org/doi/full/10.1056/NEJMoa2117344
Get every episode summarized
Each time WolverHeme Happy Hour publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from WolverHeme Happy Hour
VAR Review with Dr. Bixby: Reversing the Call on MPAL
WolverHeme Happy Hour
Bispecifics ate CAR-T's lunch: a multiple myeloma debate
WolverHeme Happy Hour
Episode 47: Cult-Like Thinking in BMT
WolverHeme Happy Hour
Spring Cleaning the Evidence from ASH 2025 with Common Sense Oncology
WolverHeme Happy Hour